Efficacy News and Research

RSS
INT-777 shows promise against metabolic syndrome

INT-777 shows promise against metabolic syndrome

Therakos commences enrollment in photopheresis Phase IIb clinical study for chronic GvHD

Therakos commences enrollment in photopheresis Phase IIb clinical study for chronic GvHD

Xeltis receives PEI conditional approval to initiate tissue-engineered cardiovascular graft study

Xeltis receives PEI conditional approval to initiate tissue-engineered cardiovascular graft study

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

Top-line primary endpoint data from Pfizer's Toviaz trial on overactive bladder

Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease

Preliminary top-line results from XenoPort's XP21279 Phase 2 trial for advanced Parkinson’s disease

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

NanoViricides submits pre-IND Meeting Request for FluCide to FDA

Converting patients to lamotrigine extended-release for epilepsy treatment found effective and safe

Converting patients to lamotrigine extended-release for epilepsy treatment found effective and safe

CTI seeks license to market Pixuvri in the E.U. for treatment of NHL

CTI seeks license to market Pixuvri in the E.U. for treatment of NHL

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

Moffitt investigators to participate with 16 oral and 50 posters presentations at 53rd ASH meeting

Epilepsy patients can benefit from gamma knife radiosurgery

Epilepsy patients can benefit from gamma knife radiosurgery

Bromide shows promise against SCN1A-associated Dravet syndrome with intractable seizures

Bromide shows promise against SCN1A-associated Dravet syndrome with intractable seizures

FDA guides novel diabetes device manufacturers towards easier approval

FDA guides novel diabetes device manufacturers towards easier approval

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

CDER, Shire enter agreement for ProAmatine clinical trial to treat symptomatic orthostatic hypotension

CDER, Shire enter agreement for ProAmatine clinical trial to treat symptomatic orthostatic hypotension

Mainz gastroenterologist awarded ERC Advanced Grant

Mainz gastroenterologist awarded ERC Advanced Grant

Mylan's NDA for Atazanavir Sulfate and Ritonavir Tablets receives tentative FDA approval through PEPFAR

Mylan's NDA for Atazanavir Sulfate and Ritonavir Tablets receives tentative FDA approval through PEPFAR

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

ASH recognizes abstract presenters at 53rd annual meeting in San Diego

Research on HIV stigma between gay men and within gay communities

Research on HIV stigma between gay men and within gay communities

JDRF supports FDA's draft guidance on artificial pancreas technology

JDRF supports FDA's draft guidance on artificial pancreas technology

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

John Theurer Cancer Center to present results of 31 studies at ASH 2011 meeting

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.